Glutamate Carboxypeptidase II (GCPII)-Targeted PET to Identify Muscle Denervation in Peripheral Nervous System Injuries

This study demonstrates that GCPII-targeted PET imaging using FDA-approved agents can noninvasively detect and monitor muscle denervation and reinnervation in peripheral nerve injuries by exploiting the persistent overexpression of GCPII in denervated muscles, offering a promising alternative to invasive electromyography.

The Gist

The Big Problem: The "Blind" Diagnosis

Imagine your body's muscles are like a vast network of electric lights in a house, and your nerves are the wires that carry electricity to them. When a wire gets cut (a nerve injury), the lights go out (muscle paralysis).

Currently, doctors have to figure out exactly which lights are out and how long they've been off. The standard way to do this is called EMG (Electromyography). Think of EMG as a mechanic sticking a sharp, vibrating probe into your muscle to see if it twitches.

• The Problem: It's painful, it's like trying to find a specific broken bulb by poking every single one in the dark, and it only checks a tiny spot. If the doctor misses a spot, they might think the wire is fine when it's actually dead. It's also hard to do this on kids or people who are in too much pain to cooperate.

The New Idea: The "Glow-in-the-Dark" Tracker

The researchers in this paper came up with a much better idea. They discovered that when a muscle loses its nerve connection (gets "denervated"), it starts screaming for help by producing a specific protein called GCPII (also known as PSMA).

Think of GCPII as a glow-in-the-dark flare that the muscle turns on when it's in trouble.

• Healthy muscle: Has very few flares (low GCPII).
• Injured muscle: Turns on thousands of flares (high GCPII).
• Healed muscle: Once the wire is fixed and the muscle gets its electricity back, it turns the flares off and goes back to normal.

The Magic Tool: The "Flashlight" (PET Scan)

The researchers realized they already have a "flashlight" that can see these flares. It's a type of medical scan called PET, and the specific chemical they use is usually reserved for finding prostate cancer. But because this chemical (let's call it the "GCPII-Tracker") is designed to stick to GCPII, it can also stick to the flares in injured muscles.

So, instead of poking the muscle with a needle, they just inject the "GCPII-Tracker" into the patient's blood. Then, they take a picture with the PET scanner.

• What they see: The injured muscles light up like a Christmas tree because they are full of flares. The healthy muscles stay dark.

What They Tested

The team didn't just guess; they tested this in three stages:

1. The Rat Lab: They cut the nerves in rats' legs.

   • Result: The injured legs lit up brightly on the scan.
   • The Fix: When they sewed the nerve back together, the rats' muscles eventually healed. As the nerves grew back, the "Christmas tree" lights on the scan slowly dimmed and went dark, proving the muscle was recovering.
   • Time: This "glow" lasted for months, giving doctors a huge window of time to see the problem.

2. The Pig Test: They did the same thing on a pig (which is closer to human size).

   • Result: The pig's injured arm muscles lit up clearly on the scan, showing exactly which muscles were disconnected.

3. The Human Test: They tried it on one real person who had a severed nerve in their arm.

   • Result: The scan showed a bright, glowing pattern in the injured arm muscles, matching exactly what the doctors expected. The healthy arm was dark.

Why This Changes Everything

This new method is like switching from poking a dark room with a stick to turning on a floodlight.

• No Pain: No needles in the muscle.
• Whole Picture: It shows every muscle in the body at once, so doctors don't miss any hidden injuries.
• Objective: The picture is clear and doesn't depend on the doctor's opinion or the patient's ability to stay still.
• Tracking Recovery: Doctors can use it to watch the "lights" dim over time to see if a surgery worked or if the nerve is healing on its own.

The Bottom Line

The researchers found that injured muscles have a unique "signature" (GCPII) that can be seen with a special camera. This could replace painful, guesswork-heavy tests with a simple, safe, and accurate scan. It's a big step toward helping doctors fix nerve injuries faster and more effectively.

Technical Summary

1. Problem Statement

Peripheral Nervous System (PNS) neuropathies, particularly traumatic peripheral nerve injuries (PNI), often lead to debilitating muscle paralysis. Accurate assessment of muscle denervation is critical for diagnosis, lesion localization, and determining treatment strategies (e.g., nerve repair vs. muscle transfer).

• Current Gold Standard Limitations: Needle electromyography (EMG) is the current standard but suffers from significant drawbacks:
  • Invasiveness and Pain: Requires percutaneous needle placement, causing patient discomfort and anxiety.
  • Sampling Errors: It tests specific muscles based on landmarks, which can miss multifocal or proximal lesions and is impractical for evaluating all potentially involved muscles.
  • Subjectivity: Interpretation is operator-dependent and difficult to reproduce across different labs.
  • Patient Constraints: Relies on patient cooperation, making it difficult for young, incapacitated, or anxious patients.
• Clinical Need: There is a critical need for a non-invasive, objective, and holistic imaging modality to quantify muscle denervation and monitor reinnervation over time.

2. Methodology

The study hypothesized that muscle denervation leads to the upregulation of Glutamate Carboxypeptidase II (GCPII), also known as Prostate-Specific Membrane Antigen (PSMA), and that this can be detected using existing FDA-approved PSMA-targeted PET agents.

Study Design & Models:

• Rodent Model (Lewis Rats):
  • Injury Types: Sciatic nerve transection (without repair), sciatic nerve transection (with immediate repair), common peroneal nerve crush, and sham surgery.
  • Timepoints: Evaluated at 2, 4, 8, 12, 16, and 24 weeks post-injury.
  • Imaging/Assays:
    • Histology: Immunofluorescence for GCPII, motor endplates ($\alpha$-bungarotoxin), and axons (neurofilament H).
    • Biochemistry: Western blot and enzymatic activity assays to quantify GCPII protein levels and function.
    • Near-Infrared (NIR) Imaging: Used YC27 (a fluorescent GCPII-targeted agent) to visualize uptake in excised hindlimbs.
    • PET Imaging: Used $^{18}$F]DCFPyL (biodistribution/gamma counting) and $^{68}$Ga]PSMA-11 (in vivo PET/MR) to measure radiotracer uptake.
    • Blocking Study: Co-administration of ZJ-43 (a competitive GCPII inhibitor) to confirm tracer specificity.
• Large Animal Model (Porcine):
  • Model: Bilateral median nerve transection in a Yorkshire pig (16 weeks post-injury).
  • Imaging: Whole-body $^{68}$Ga]PSMA-11 PET/CT using a clinical scanner.
• Human Case Study:
  • Patient: A woman with a complete left radial nerve injury (15 weeks post-injury).
  • Imaging: Clinical $^{18}$F]DCFPyL PET/CT using a standard prostate cancer imaging protocol.

3. Key Contributions

• Discovery of a Novel Biomarker: Demonstrated that GCPII is persistently over-expressed in denervated skeletal muscle and that this expression normalizes upon reinnervation.
• Repurposing of Clinical Agents: Validated the use of FDA-approved PSMA-PET agents ($^{18}$F]DCFPyL and $^{68}$Ga]PSMA-11) for a non-oncologic indication (muscle denervation).
• Holistic Imaging: Provided a method to image all affected muscle groups simultaneously, overcoming the sampling limitations of EMG.
• Translational Pathway: Successfully bridged findings from molecular biology (rats) to large animal models (pigs) and a human patient, proving clinical feasibility.

4. Key Results

• GCPII Upregulation:
  • Histology showed GCPII staining localized to the myocyte membrane (near subsarcolemmal mitochondria) rather than just neuromuscular junctions.
  • Quantification: Denervated muscles showed 4.0x higher GCPII protein expression and 4.3x higher enzymatic activity compared to controls. This elevation persisted for at least 24 weeks in rats.
• NIR Imaging (YC27):
  • YC27 uptake was significantly elevated in denervated muscles at 2, 4, and 16 weeks.
  • Uptake resolved in muscles that underwent reinnervation (e.g., after nerve repair or nerve crush recovery) but remained high in unrepaired, chronically denervated muscles.
• PET Imaging ($^{18}$F]DCFPyL & $^{68}$Ga]PSMA-11):
  • Rats: Denervated gastrocnemius muscles showed approximately 2x higher uptake than innervated controls.
    • At 16 weeks, unrepaired muscles maintained high uptake (0.36 %ID/g), while repaired muscles declined toward baseline (0.19 %ID/g).
    • Blocking with ZJ-43 eliminated the uptake difference, confirming specificity to GCPII.
  • Pigs: $^{68}$Ga]PSMA-11 PET/CT showed 1.88x higher SUVmean in median nerve-innervated (denervated) forearm muscles compared to naïve muscles.
  • Human: The patient with radial nerve palsy showed 2.0x higher uptake in the denervated forearm extensor muscles compared to the contralateral healthy arm. The pattern mirrored preclinical findings.
• Specificity: The increased uptake was specific to denervation, as it was not observed in sham-operated controls and was reversible with reinnervation.

5. Significance and Implications

• Clinical Translation: Because $^{18}$F]DCFPyL and $^{68}$Ga]PSMA-11 are already FDA-approved and widely available for prostate cancer imaging, GCPII-PET for nerve injury is rapidly translatable to clinical practice without the need for new drug development.
• Superiority to EMG: GCPII-PET offers a non-invasive, quantitative, and reproducible alternative to EMG. It eliminates sampling errors by imaging the entire muscle volume and provides objective data that can be independently verified.
• Monitoring Recovery: The ability to track the decline of GCPII uptake allows clinicians to monitor the success of nerve repairs or spontaneous regeneration longitudinally, potentially guiding the timing of surgical interventions (e.g., free functional muscle transfer).
• Broader Applicability: This approach is applicable to complex conditions where EMG is difficult, such as proximal plexus injuries, Parsonage-Turner syndrome, and spinal cord injuries with lower motor neuron involvement.
• Mechanistic Insight: The study suggests that GCPII upregulation is a compensatory response to denervation-induced protein homeostasis changes (involving glutamate signaling and ubiquitin-proteasome pathways), offering potential new therapeutic targets for preventing muscle atrophy.

Conclusion:
The study establishes GCPII-PET as a promising, objective, and holistic diagnostic tool for peripheral nerve injuries. It addresses critical limitations of current standards and demonstrates immediate potential for clinical adoption to improve the management of PNS neuropathies.